Effects of Dual Cyclooxygenase-2 and Carbonic Anhydrase Inhibition
|ClinicalTrials.gov Identifier: NCT00780325|
Recruitment Status : Terminated (A total of three parts were planned for this study. The sponsor funded only Part 1, so that neither Part 2 nor Part 3 of this study has been conducted.)
First Posted : October 27, 2008
Last Update Posted : February 6, 2014
University of Pennsylvania
Information provided by (Responsible Party):
Carsten Skarke, University of Pennsylvania
No Study Results Posted on ClinicalTrials.gov for this Study
|Recruitment Status :||Terminated|
|Actual Primary Completion Date :||July 2013|
|Actual Study Completion Date :||July 2013|
Publications of Results:
Skarke C, Alamuddin N, Lawson JA, Cen L, Propert KJ, Fitzgerald GA. Comparative impact on prostanoid biosynthesis of celecoxib and the novel nonsteroidal anti-inflammatory drug CG100649. Clin Pharmacol Ther. 2012 Jun;91(6):986-93. doi: 10.1038/clpt.2012.3. Epub 2012 Jan 25.
Hirankarn S, Barrett JS, Alamuddin N, FitzGerald GA, Skarke C. GCG100649, A Novel Cyclooxygenase-2 Inhibitor, Exhibits a Drug Disposition Profile in Healthy Volunteers Compatible With High Affinity to Carbonic Anhydrase-I/II: Preliminary Dose-Exposure Relationships to Define Clinical Development Strategies. Clin Pharmacol Drug Dev. 2013 Oct;2(4):379-86. doi: 10.1002/cpdd.47. Epub 2013 Jul 25.